Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
40
RLYB Quote, Financials, Valuation and Earnings
Last price:
$0.46
Seasonality move
:
-6.94%
Day range:
$0.43 - $0.50
52-week range:
$0.22 - $1.54
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
23.88x
P/B ratio:
0.35x
Volume:
1.4M
Avg. volume:
5.7M
1-year change:
-67.29%
Market cap:
$18.9M
Revenue:
$636K
EPS (TTM):
-$1.09
Analysts' Opinion
-
Consensus RatingRallybio has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $1.00, Rallybio has an estimated upside of 119.93% from its current price of $0.45.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $0.45.
Fair Value
-
According to the consensus of 4 analysts, Rallybio has 119.93% upside to fair value with a price target of $1.00 per share.
RLYB vs. S&P 500
-
Over the past 5 trading days, Rallybio has overperformed the S&P 500 by 14.14% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Rallybio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rallybio has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Rallybio reported revenues of $212K.
Earnings Growth
-
Rallybio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Rallybio reported earnings per share of -$0.21.
Enterprise value:
-35.6M
EV / Invested capital:
--
Price / LTM sales:
23.88x
EV / EBIT:
--
EV / Revenue:
-41.95x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.81x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-64.78%
Net Income Margin (TTM):
-5682.19%
Return On Equity:
-67.73%
Return On Invested Capital:
-72.31%
Operating Margin:
-4561.32%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $848K | -- | $212K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$71.9M | -$80.3M | -$50.4M | -$19.8M | -$9.7M | |
| EBITDA | -$71.8M | -$80.2M | -$50.3M | -$19.8M | -$9.6M | |
| Diluted EPS | -$2.06 | -$1.87 | -$1.09 | -$0.47 | -$0.21 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $128.7M | $167.8M | $161.3M | $98.5M | $57.4M | |
| Total Assets | $129.3M | $169.4M | $162.3M | $99.4M | $58M | |
| Current Liabilities | $6.1M | $5.8M | $6.8M | $10.1M | $3.9M | |
| Total Liabilities | $188.1M | $6.3M | $7.1M | $10.2M | $3.9M | |
| Total Equity | -$58.8M | $163M | $155.2M | $89.2M | $54.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$62.3M | -$57M | -$44M | -$15.5M | -$10.2M | |
| Cash From Investing | -$30.5M | $36.5M | $34.3M | $10.3M | $11.1M | |
| Cash From Financing | $50.9M | $282K | $5.2M | -- | -- | |
| Free Cash Flow | -$62.3M | -$57M | -$44M | -$15.5M | -$10.2M | |
RLYB
Sector
Market Cap
$18.9M
$35.2M
Price % of 52-Week High
29.53%
48.58%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-67.29%
-36.85%
Beta (5-Year)
--
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.44
200-day SMA
Sell
Level
$0.71
Bollinger Bands (100)
Buy
Level
0.26 - 0.6
Chaikin Money Flow
Sell
Level
-23.8M
20-day SMA
Buy
Level
$0.38
Relative Strength Index (RSI14)
Buy
Level
60.44
ADX Line
Buy
Level
39.87
Williams %R
Neutral
Level
-52.5542
50-day SMA
Buy
Level
$0.35
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
215M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.1551)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Stock Forecast FAQ
In the current month, RLYB has received 1 Buy ratings 3 Hold ratings, and 0 Sell ratings. The RLYB average analyst price target in the past 3 months is $1.00.
-
Where Will Rallybio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rallybio share price will rise to $1.00 per share over the next 12 months.
-
What Do Analysts Say About Rallybio?
Analysts are divided on their view about Rallybio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rallybio is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Rallybio's Price Target?
The price target for Rallybio over the next 1-year time period is forecast to be $1.00 according to 4 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is RLYB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rallybio is a Hold. 3 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of RLYB?
You can purchase shares of Rallybio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rallybio shares.
-
What Is The Rallybio Share Price Today?
Rallybio was last trading at $0.46 per share. This represents the most recent stock quote for Rallybio. Yesterday, Rallybio closed at $0.45 per share.
-
How To Buy Rallybio Stock Online?
In order to purchase Rallybio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is down 0.24% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 11.39% over the past day.
Buy
72
MNPR alert for Jul 18
Monopar Therapeutics [MNPR] is up 1.57% over the past day.
